McGuireWoods advised Biofrontera Inc., the U.S.
subsidiary of international biopharmaceutical company Biofrontera AG, in
its initial public offering that closed Nov. 2, 2021, and a $15 million
private placement in public equity (PIPE) offering that closed Dec. 1,
Biofrontera specializes in commercialization of pharmaceutical products
that treat dermatological conditions and diseases caused primarily by sun
damage to the skin. Proceeds from the two transactions will enable the
company to achieve its near-term business goals, including expanding its
commercial position across the United States.
New York partner
Stephen Older and Charlotte associate
Andrew Terjesen led the McGuireWoods deal team, which included partner
Seth Goldsamt and associate Samar Khan in New York, Charlotte counsel
David Wolpa, Charlotte healthcare partner
Kate Hardey and Chicago healthcare associate
McGuireWoods has served as go-to U.S. counsel for Biofrontera AG for the
past six years. Firm lawyers represented the company in its 2018 U.S.
initial public offering of American depositary shares and several other
securities offerings, as well as the acquisition of dermatology company
Cutanea Life Sciences Inc. The firm also has advised Biofrontera AG on U.S.
securities law and regulatory issues and various litigation matters.
“We value our longstanding relationship with Biofrontera and were proud to
assist the company in closing these significant transactions, which
demonstrate the capabilities of our securities practice,” Older said.
McGuireWoods consistently ranks among the leading law firms for advising
corporate issuers and underwriters in U.S. capital markets transactions and
global recognition for its work representing clients in corporate and securities matters.